Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. IK Small Cap I Fund divests Touristry Group to TGH
Mandate

IK Small Cap I Fund divests Touristry Group to TGH

April 20, 2018 M&A

Vinge has advised IK Small Cap I Fund in connection with the divestment of Touristry Group Holding AB, a market leading operator of sightseeing buses and boats and a provider of tourism related services, to Amsterdam-based Tourism Group Holding B.V. (“TGH”).

Touristry is a market leading provider of tourism related services in the Nordics, primarily focused on bus and boat sightseeing (“Hop-On, Hop-Off”). Headquartered in Stockholm, the company has grown rapidly by expanding with its main brands Red Buses and Red Sightseeing and today provides services to over 2 million tourists per year in the Nordic region. 

Vinge’s team consisted of, among others, Partner Jonas Bergström together with associates Filip Öhrner and Michaela Cronemy.
 

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

 Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

 Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026